CAZZANIGA, MARINA ELENA

CAZZANIGA, MARINA ELENA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 132 (tempo di esecuzione: 0.058 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 01 - Articolo su rivista 2025 Malighetti, FedericaVilla, MatteoPelucchi, SaraAroldi, AndreaCortinovis, Diego LuigiCazzaniga, Marina ElenaMologni, LucaRamazzotti, DanieleCordani, Nicoletta +
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 01 - Articolo su rivista 2024 Cazzaniga M. E.Zambelli A. +
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160) 99 - Altro 2024 Cazzaniga M. +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 01 - Articolo su rivista 2024 Foti G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M.Bellani G.Bruno R.Biondi A.Bettini L. R.Beretta I. +
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 01 - Articolo su rivista 2024 Bonfanti P.Lombardi A.Invernizzi P.Gerussi A.Citerio G.Biondi A.Valsecchi M. G.Cazzaniga M. E.Foti G.Bettini L. R. +
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M.Antonazzo I. C.Mantovani L. G.Cortesi P. A. +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
A multidisciplinary approach to screen the post-COVID-19 conditions 01 - Articolo su rivista 2023 Squillace N.Rossi E.Bellelli G.Pozzi M.Luppi F.Strepparava M. G.Ferrarese C.Bonfanti P.Bellani G.Biondi A.Cazzaniga M. E.Citerio G.Foti G.Valsecchi M. G.Beretta E. M.Spolti A.Ferlicca D.Bettini F.Bellin V.Meroni V.Gatti S.Bronco A.Ripa C.Sosio S.Faverio P.Monzani A.Ferrara M. C.Zarcone C.Beretta S.Salvarani V. +
A second update on mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2023 Invernizzi, PietroGerussi, AlessioBiondi, AndreaBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria G.Cazzaniga, MarinaFaverio, PaolaBonfanti, Paolo +
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 01 - Articolo su rivista 2023 Cazzaniga M. E. +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Aromatase inhibitors: the journey from the state of the art to clinical open questions 01 - Articolo su rivista 2023 Cazzaniga M. +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Cordani N.Paglia G.Meanti R.Cerrito M. G.Villa C.Mauri M.Mologni L.Torsello A.Cazzaniga M. E. +
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 01 - Articolo su rivista 2023 Cazzaniga M. +
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 01 - Articolo su rivista 2023 Cazzaniga M. E. +
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 01 - Articolo su rivista 2023 Bonfanti P.Cazzaniga M. E. +